C4 Therapeutics, Inc Share Price Today: Live Updates & Key Insights

C4 Therapeutics, Inc share price today is $2.72, up 3.45%. The stock opened at $2.615 against the previous close of $2.61, with an intraday high of $2.85 and low of $2.605.

C4 Therapeutics, Inc Share Price Chart

C4 Therapeutics, Inc

us-stock
To Invest in {{usstockname}}
us-stock

C4 Therapeutics, Inc Share Price Performance

$2.72 0.0345(3.45%) CCCC at 23 Mar 2026 12:23 PM Biotechnology
Lowest Today 2.605
Highest Today 2.85
Today’s Open 2.615
Prev. Close 2.61
52 Week High 3.82
52 Week Low 1.09
Day’s Range: Low 2.605 High 2.85
52-Week Range: Low 1.09 High 3.82
1 day return -
1 Week return -0.91
1 month return +16.81
3 month return +29.97
6 month return +4.03
1 year return +22.62
3 year return -25.13
5 year return -93.28
10 year return -

C4 Therapeutics, Inc Institutional Holdings

RA Capital Management, LLC 8.20

Bain Capital Life Sciences Investors, LLC 7.35

Lynx1 Capital Management, LP 7.27

Soleus Capital Management, L.P. 7.23

Morgan Stanley - Brokerage Accounts 5.10

Vanguard Group Inc 4.49

Wasatch Advisors LP 4.45

Vanguard Total Stock Mkt Idx Inv 2.96

Wasatch Ultra Growth 2.90

Bank of America Corp 2.10

SILVERARC CAPITAL MANAGEMENT, LLC 2.04

Susquehanna International Group, LLP 1.82

Renaissance Technologies Corp 1.64

BlackRock Inc 1.64

Two Sigma Investments LLC 1.55

Orbimed Advisors, LLC 1.44

Millennium Management LLC 1.22

Two Sigma Advisers, LLC 1.09

Geode Capital Management, LLC 1.01

TANG CAPITAL MANAGEMENT LLC 0.92

Vanguard Institutional Extnd Mkt Idx Tr 0.90

Jane Street Group LLC 0.90

Biotech Growth Ord 0.79

iShares Biotechnology ETF 0.60

The Goldman Sachs Group Inc 0.47

Fidelity Extended Market Index 0.43

Schwab US Small-Cap ETF™ 0.39

Renaissance Global Small Cap 0.28

Wasatch Long Short Alpha Composite 0.25

Wasatch Long/Short Alpha Institutional 0.25

Invesco RAFI US 1500 Small-Mid ETF 0.25

Blackrock Extended Mkt Fund CF 0.25

Extended Equity Market Fund K 0.21

iShares Micro-Cap ETF 0.19

A4Investments SICAV SIF ACCI IlanaA2EURH 0.16

Fidelity Total Market Index 0.16

Fidelity Enhanced Small Cap ETF 0.16

Spartan Extended Market Index Pool F 0.13

Bridgeway Ultra-Small Company Market 0.12

Wasatch Global Small Cap Composite 0.11

C4 Therapeutics, Inc Market Status

Strong Buy: 4

Buy: 0

Hold: 4

Sell: 0

Strong Sell: 0

C4 Therapeutics, Inc Fundamentals

Market Cap 263.46 M

PB Ratio 1.0268

PE Ratio 0.0

Enterprise Value 74.91 M

Total Assets 359.08 M

Volume 3310767

C4 Therapeutics, Inc Company Financials

Annual Revenue FY23:20349000 20.3M, FY22:31096000 31.1M, FY21:45785000 45.8M, FY20:33195000 33.2M, FY19:21381000 21.4M

Annual Profit FY23:null 0.0M, FY22:31096000 31.1M, FY21:45785000 45.8M, FY20:33195000 33.2M, FY19:21381000 21.4M

Annual Net worth FY23:-134924000 -134.9M, FY22:-126499000 -126.5M, FY21:-86037000 -86.0M, FY20:-66335000 -66.3M, FY19:-34099000 -34.1M

Quarterly Revenue Q3/2025:11230000 11.2M, Q2/2025:6463000 6.5M, Q1/2025:7238000 7.2M, Q3/2024:15362000 15.4M, Q2/2024:12006000 12.0M

Quarterly Profit Q3/2025:11230000 11.2M, Q2/2025:6463000 6.5M, Q1/2025:7238000 7.2M, Q3/2024:13306000 13.3M, Q2/2024:9961000 10.0M

Quarterly Net worth Q3/2025:-32166000 -32.2M, Q2/2025:-26020000 -26.0M, Q1/2025:-26322000 -26.3M, Q3/2024:-24666000 -24.7M, Q2/2024:-17716000 -17.7M

About C4 Therapeutics, Inc & investment objective

Company Information C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 104

Industry Biotechnology

CEO Mr. Andrew J. Hirsch M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

C4 Therapeutics, Inc FAQs

What is the share price of C4 Therapeutics, Inc today?

The current share price of C4 Therapeutics, Inc is $2.72.

Can I buy C4 Therapeutics, Inc shares in India?

Yes, Indian investors can buy C4 Therapeutics, Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy C4 Therapeutics, Inc shares in India?

You can easily invest in C4 Therapeutics, Inc shares from India by:

Can I buy fractional shares of C4 Therapeutics, Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of C4 Therapeutics, Inc?

C4 Therapeutics, Inc has a market cap of $263.46 M.

In which sector does C4 Therapeutics, Inc belong?

C4 Therapeutics, Inc operates in the Biotechnology sector.

What documents are required to invest in C4 Therapeutics, Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of C4 Therapeutics, Inc?

The PE ratio of C4 Therapeutics, Inc is N/A and the PB ratio is 1.03.